Peripheral CB1 Partial Agonists to Limit Psychoactive Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cannabinoid receptor (CB) therapeutics face limitations due to adverse effects such as marijuana-like psychoactivity and addictive tendencies, restricting their therapeutic potential, necessitating the development of alternative approaches that target CB-mediated signaling pathways without CNS penetrating modulators.
Innovation Solution
Development of peripheral partial agonists of CB receptors, including CB1 and CB2 selectivity, to treat diseases and disorders mediated by CB-signaling pathways, such as pain and metabolic disorders, without the negative side effects associated with CNS penetrating modulators.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CNS penetrating cannabinoid modulators are used, then therapeutic effects on CB-mediated pathways are achieved, but adverse effects such as psychoactivity and addictive tendencies occur
Solution Approach 1:
The patent segments the cannabinoid receptor system by developing peripherally restricted agonists that selectively activate CB1 receptors in peripheral tissues (gut, liver, pancreas) without crossing the blood-brain barrier. This spatial segmentation separates the therapeutic action in peripheral CB-mediated pathways from the CNS, eliminating psychoactivity while maintaining therapeutic efficacy for conditions like pain, inflammation, and metabolic disorders.
Solution Approach 2:
The invention applies local quality by creating compounds with selective peripheral activity through specific molecular structures (e.g., compounds of Formula I with particular substituent patterns) that confer CB1 selectivity and peripheral restriction. The local quality of peripheral tissue penetration versus CNS penetration is controlled by the pharmacokinetic properties of the compounds, allowing targeted activation only where needed.
2Reliability
If full CB1 agonists are used, then CB-mediated therapeutic effects are achieved, but psychoactive side effects are produced
Solution Approach 1:
The patent employs partial agonism at CB1 receptors, where the compounds provide sub-maximal activation compared to full agonists like Δ9-THC. This partial action is sufficient to activate downstream therapeutic pathways (anti-inflammatory, analgesic, metabolic regulation) while producing significantly lower psychoactive effects, as the receptor activation is incomplete enough to avoid full psychoactive syndrome.
Solution Approach 2:
The invention converts the potentially harmful full agonist activity into a beneficial partial agonist approach. By designing compounds that provide just enough activation for therapeutic effect but not enough for psychoactivity, the harmful aspect of CB1 activation (psychoactivity) is transformed into a controllable parameter that can be optimized for safety while maintaining efficacy.
3Object-affected harmful factors
If peripherally restricted CB1 agonists are developed, then psychoactivity is reduced, but therapeutic window is limited
Solution Approach 1:
The patent applies parameter changes by systematically varying molecular parameters of the indazole derivative compounds (substituents at specific positions, stereochemistry, functional groups) to optimize the balance between peripheral potency and CNS penetration. By adjusting parameters such as lipophilicity, hydrogen bonding capacity, and steric properties, the compounds achieve high peripheral CB1 affinity while maintaining low CNS penetration, thereby expanding the therapeutic window.
Data Source
AI summary
The present disclosure includes peripheral partial agonists of one or more CB receptors, including modulation of CB1, both with and without CB2 selectivity. The compounds of the present disclosure may be useful in the treatment of diseases and disorders mediated by a CB-signaling pathway, including but not limited to pain, gastrointestinal disorders, metabolic disorders, and liver disorders, such as alcoholic steatohepatitis or nonalcoholic steatohepatitis (NASH).